Last reviewed · How we verify
NCT05221372: START-TKI
ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
trial in Non Small Cell Lung Cancer in 1,300 participants. Currently enrolling.
1 January 2031
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,300 |
| Start date | 2 February 2017 |
| Primary completion | 1 January 2031 |
| Estimated completion | 1 January 2031 |
| Sites | 1 location across Netherlands |
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
- Liquid Biopsy — all drugs for Liquid Biopsy →
- Tyrosine Kinase Inhibitor — all drugs for Tyrosine Kinase Inhibitor →
Sponsor
Erasmus Medical Center
Who can join
18 and older, any sex, with Non Small Cell Lung Cancer or Liquid Biopsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05221372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05221372 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 18 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05221372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing